Mitsufuji Hisashi

CMAR_A_207170 4883..4892

K. Naoki, M. Katagiri, S. Igawa, 2019 .

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study

K. Naoki, M. Katagiri, S. Igawa, 2019, Cancer management and research.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

K. Naoki, M. Katagiri, S. Igawa, 2019, Thoracic cancer.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

K. Naoki, Takashi Sato, S. Igawa, 2021, Investigational New Drugs.

Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma

K. Naoki, S. Igawa, J. Sasaki, 2023, Investigational New Drugs.